https://blueblood.com.tw/wp-content/uploads/2024/09/dna-genetic-biotechnology-science-with-scientist-rsquo-s-hands-disruptive-technology-remix.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302024-06-01 12:00:472025-07-01 10:21:20Completed mass production of dissolvable microneedle products.
https://blueblood.com.tw/wp-content/uploads/2024/09/3d-render-medical-background-with-dna-strands-connecting-dots-拷貝.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302024-01-01 12:00:282025-06-24 17:38:42BB-101 Phase II clinical trial approved by the Ministry of Economic Affairs, receiving a subsidy of NT$34 million under the ‘A+ Enterprise Innovation R&D Program – Fast-Track Clinical Trial Review.’
Completed mass production of dissolvable microneedle products.
Licensed androgenic alopecia technology to Sanar Biotech Corp. through patent valuation.
BB-101 Phase II clinical trial approved by the Ministry of Economic Affairs, receiving a subsidy of NT$34 million under the ‘A+ Enterprise Innovation R&D Program – Fast-Track Clinical Trial Review.’